Catalog No.
PAD17201
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
Ipilimumab
Tested applications
ELISA: 1:4000-1:8000
Target
Rabbit polyclonal to Yervoy.
Specificity
The product is specific for Ipilimumab. This antibody serves as an excellent positive control for Ipilimumab immunogenicity (ADA) assays.
Concentration
1.6 mg/ml
Purification
Purified by antigen affinity column.
Accession
CAS: 477202-00-9
Applications
ELISA
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.
Background
Ipilimumab (Yervoy) is a humanized monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of patients with unresectable or metastatic melanoma. Ipilimumab works to activate the immune system by targeting CTLA-4 (Cytotoxic T-lymphocyte protein 4), a negative regulator of cytotoxic T-lymphocyte activity. Ipilimumab binds to CTLA-4, blocking the inhibitory signal, which allows the cytotoxic T-lymphocytes to destroy the cancer cells.
Organ-Specific Responses to Nivolumab Plus Ipilimumab in Advanced Hepatocellular Carcinoma: A Multicenter, Retrospective Study., PMID:40488227
CTLA-4 blockade in ovarian cancer immunotherapy: Mechanisms and clinical strategies., PMID:40482550
Surgical considerations for tumour-infiltrating lymphocyte therapy in melanoma: results from a randomized phase III trial., PMID:40474841
Immune-mediated enterocolitis is associated with immune checkpoint inhibitors: A pharmacovigilance study from the FDA Adverse Event Reporting System (FAERS) database., PMID:40465755
Fc-optimized anti-CTLA-4 antibodies increase tumor-associated high endothelial venules and sensitize refractory tumors to PD-1 blockade., PMID:40460830
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced melanoma with BRAFV600E or BRAFV600K mutations (EBIN): an international, open-label, randomised, controlled, phase 2 study., PMID:40449497
Correlation Between Body Mass Index and Clinical Outcomes in Advanced Renal Cell Carcinoma Patients., PMID:40425321
Using liquid biopsies to guide treatment and monitor response in BRAF V600E positive adenocarcinoma of unknown primary., PMID:40425210
Multisystem immune-related adverse reactions with immune checkpoint inhibitors., PMID:40421943
Adjuvant Immunotherapy in Microsatellite Instability-High Colon Cancer: A Literature Review on Efficacy, Challenges, and Future Directions., PMID:40415356
A treatment-related death predictive score for treatment-naïve advanced non-small cell lung cancer., PMID:40409025
Real-world efficacy and safety of nivolumab and ipilimumab in metastatic renal cell carcinoma: a Polish multicenter study., PMID:40391586
Rationale and feasibility of a rapid integral biomarker program that informs immune-oncology clinical trials: the ADVISE trial., PMID:40389374
Interplay between sarcopenia, GDF-15, and the efficacy of nivolumab plus ipilimumab in patients with mismatch repair deficient metastatic colorectal cancer: final survival analysis of the phase II GERCOR NIPICOL study., PMID:40389373
[Renal injury during combination immunotherapy (ipilimumab + nivolumab) in patients with metastatic renal cell cancer who previously underwent nephrectomy]., PMID:40377638
Nivolumab plus low-dose ipilimumab in hypermutated HER2-negative metastatic breast cancer: a phase II trial (NIMBUS)., PMID:40360544
An Extremely Rare Case of Immune Checkpoint Inhibitors-Related Hypoparathyroidism and a Critical Literature Review., PMID:40356787
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial., PMID:40349714
The emerging role of lymphocyte-activation gene 3 targeting in the treatment of solid malignancies., PMID:40344213
Nivolumab- and ipilimumab-induced myositis, myasthenia gravis, and myocarditis in a patient with metastatic melanoma., PMID:40343457
Prognostic and predictive value of IDO expression in metastatic melanoma treated with Ipilimumab., PMID:40334245
The Practical Side Effects Experienced in Patients Treated With Medications Approved for Melanoma., PMID:40327576
Novel chimeric CTLA-4 B-cell epitope peptide vaccines demonstrate effective anti-tumor immunity with/without PD1/PDL1 blockade in multiple syngeneic murine models of breast and colorectal cancers., PMID:40325996
[Bilateral carpal tunnel syndrome in a patient with malignant melanoma undergoing adjuvant pembrolizumab therapy]., PMID:40314804
Immune Checkpoint Inhibitor-induced Uveitis: Disproportionality and Timing Analyses of the Japanese Pharmacovigilance Database., PMID:40295055
Model-Informed Immunogenicity Assessment of Nivolumab as Monotherapy and in Combination with Ipilimumab., PMID:40281256
Case Report: Durable remission after abscopal effect following transcatheter hepatic arterial embolization in a patient with mucosal melanoma refractory to immunotherapy., PMID:40276508
Large vessel vasculitis associated with atezolizumab., PMID:40268701
A Real-Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune-Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus Ipilimumab., PMID:40249663
Impact of steroid dose and timing on efficacy of combination PD-1/CTLA-4 blockade., PMID:40248956
Anti-CTLA-and anti-PD-1 immune checkpoint inhibitor antibodies impair human sperm motility in-vitro., PMID:40230698
A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCC., PMID:40212021
Metabolomic signatures in liquid biopsy are associated with overall survival in metastatic melanoma patients treated with immune checkpoint inhibitor therapy., PMID:40211360
Off-Label Use of First-Line Immunotherapy for Metastatic Renal Cell Carcinoma., PMID:40186898
Molecular analysis of immune checkpoint inhibitor associated erythema nodosum-like toxicity., PMID:40181973
Prediction, prevention, and precision treatment of immune checkpoint inhibitor neurological toxicity using autoantibodies, cytokines, and microbiota., PMID:40181971
Phase II Study of Nivolumab and Ipilimumab for Treatment of Metastatic/Recurrent Adenoid Cystic Carcinoma (ACC) of all Anatomic Sites of Origin and Other Malignant Salivary Gland Tumors., PMID:40166913
Management of metastatic melanoma with combinations including PD-1 inhibitors., PMID:40159098
Immune Checkpoint Inhibitor-associated Pneumonitis: A Narrative Review., PMID:40145913
Exploring the Dynamics of Immune Checkpoint Inhibitor-Induced Eosinophilia in Advanced/Metastatic Melanoma: A Comprehensive Retrospective Analysis., PMID:40145321
Physiologically Based Pharmacokinetic Models for Infliximab, Ipilimumab, and Nivolumab Developed with GastroPlus to Predict Hepatic Concentrations., PMID:40143035
Dramatic Responses to High-Dose Ipilimumab Plus Temozolomide After Progression on Standard- or Low-Dose Ipilimumab in Advanced Melanoma., PMID:40136348
Two cases of advanced melanoma with BRAF L597 mutation: Options for systemic treatment., PMID:40130804
Monoclonal antibodies as adjuvant therapies for resected melanoma., PMID:40125987
Influence of high-fiber diet on ipilimumab-induced gastrointestinal toxicity in metastatic melanoma., PMID:40112923
Reactivation of CTLA4-expressing T cells accelerates resolution of lung fibrosis in a humanized mouse model., PMID:40100323
TNF signature in advanced melanoma patients treated with immune checkpoint inhibitors: Results from the MELANFα clinical study., PMID:40098565
Efficacy and Safety of Ipilimumab Plus Anti-PD-1/PD-L1 Antibodies Combination Therapy in Advanced Hepatocellular Carcinoma Patients Progressing After Multiple Lines of Treatment: A Retrospective Multicenter Study., PMID:40092399
Neoadjuvant treatment with immune checkpoint inhibitors in patients with melanoma: A real-life retrospective study., PMID:40091460
Sustained Immunotherapy Response in Metastatic Brain Melanoma Through 2 Pregnancies., PMID:40083082
For research use only. Not for human or drug use.
